LS 696 v. Uber Technologies - Personal Injury Product Liability

Jane Doe LS 696 filed a civil complaint against Uber Technologies, Inc. and all defendants in the Northern District of California on April 2, 2026. The case is based on diversity jurisdiction and concerns personal injury product liability. This is a routine new case filing with no immediate compliance implications for the broader industry.

Lewis v. Jaguar Land Rover North America, LLC - Product Liability/Contract

Lewis filed a civil product liability and contract action against Jaguar Land Rover North America, LLC in the Northern District of California. The defendant removed the case from Santa Clara Superior Court (Case No. 26cv487508) to federal court based on diversity jurisdiction. The case involves a vehicle purchase or lease dispute.

Hart Jr. v. Musci et al - Medical Malpractice

Eugene Hart Jr. filed a medical malpractice complaint in the Northern District of California against Dr. Thomas J. Musci and others (Robert Lee Hart, Lynette Lewis). The plaintiff also filed a motion to proceed in forma pauperis. The court issued an Initial Case Management Scheduling Order setting the Case Management Statement deadline for July 3, 2026 and the Initial Case Management Conference for July 10, 2026. A consent/declination regarding the assigned magistrate judge is due by April 15, 2026.

Strike 3 Holdings v. John Doe - Copyright Infringement

The United States District Court for the Northern District of California received a copyright infringement complaint filed by Strike 3 Holdings, LLC against a John Doe defendant identified by IP address 172.9.232.173. The plaintiff alleges federal copyright infringement and seeks damages under the Copyright Act. Corporate parent General Media Systems, LLC is disclosed as an interested entity.

Strike 3 Holdings sues John Doe for copyright infringement

Strike 3 Holdings sues John Doe for copyright infringement

Determination of Regulatory Review Period for EMRELIS Patent Extension

FDA has determined the regulatory review period for EMRELIS, a human biological product, and published this determination as required by law. The notice allows interested parties to comment on the accuracy of dates and to petition FDA regarding due diligence during the review period.

Medical Device Variance Renewal - Redhouse Productions

FDA CDRH approved a variance renewal for Redhouse Productions (FDA-2023-V-2753-0004). The variance allows deviation from standard medical device manufacturing requirements under specific conditions. The renewal maintains previously granted flexibilities for the regulated entity.

Complaint Regarding Potential Regulatory Violation

FDA posted a complaint under docket FDA-2026-H-3081-0001 on April 3, 2026. The complaint, authored by CTP (Center for Tobacco Products), relates to a potential regulatory violation. No documents are currently available for review on regulations.gov.

VYLOY Patent Extension Regulatory Review Period Determination

The FDA has determined the regulatory review period for VYLOY, a human biological product, and published this notice as required under 35 U.S.C. 156. The notice invites comments on whether any published dates are incorrect by June 2, 2026, and allows interested persons to petition FDA regarding due diligence by September 30, 2026.

ENFLONSIA Regulatory Review Period Determination

FDA has determined the regulatory review period for ENFLONSIA, a human biological product, as required by 35 U.S.C. 156 for patent extension purposes. The notice invites public comment on whether the published dates are incorrect and allows interested parties to petition FDA regarding the applicant's due diligence during the review period.